Fierce Biotech
AstraZeneca’s in vivo CAR-T bet eradicates cancer in 3 of 5 patients, but death mars dataset
AstraZeneca isn’t letting a death in a China trial detract from the potential of its $1 billion in vivo bet, even as the candidate’s safety and efficacy profile have so far failed to separate it from traditional CAR-T therapies.